The effect of rivaroxaban on aPTT and anti-Xa levels
Research type
Research Study
Full title
Laboratory Measurement of Rivaroxaban using PT, aPTT, anti-Xa level and HPLC-MS/MS
IRAS ID
197579
Contact name
Isla Thom
Contact email
Sponsor organisation
University of Aberdeen/NHS Grampian
Duration of Study in the UK
0 years, 4 months, 1 days
Research summary
The purpose of this study is to gain a better undertsanding of how the routine tests and reagents currently used in Haematology for assessing coagulation are affected by a new direct oral anticoagulant Rivaroxaban. Samples will be obtained by freezing an aliquot of excess plasma from a routine blood test from patients where the clinical details state rivaroxaban. This will be batch tested for prothrombin time and activated partial thromboplastin time (routine tests) as well as a new specifically calibrated rivaroxaban anti-Xa assay. Mass spectrometry will also be performed in order to obtain the exact concentration of drug in the sample. It is hoped that a correlation will be obtained between routine tests and anti-Xa activity and concentration so that interpretation of routine tests from patients on rivaroxaban can be simplified for lab staff and medical staff.
REC name
South West - Cornwall & Plymouth Research Ethics Committee
REC reference
16/SW/0152
Date of REC Opinion
18 May 2016
REC opinion
Favourable Opinion